Hello! I’m Holly Hartman, a PhD candidate in Biostatistics at the University of Michigan. Check out my work, and get in touch below.
Cancer treatments are being delayed due to COVID-19, but is this always the best option? I built an app to create personalized survival estimates for cancer patients during the COVID-19 pandemic
Many clinical trial designs rely on dichotomous end points. I explore how to allow for continuous outcomes while maintaining trial properties and statistical features.
Observational studies can provide answers to research questions and uses less resources than a randomized clinical trial. Do they provide accurate answers about treatment comparisons?
Hello! I’m Holly Hartman, a PhD candidate in Biostatistics at the University of Michigan.
I received my BS in mathematics and molecular and cellular biology from the University of Puget Sound. I also have my MS in bio statistics from the University of Alabama at Birmingham.
My current work is in methodological improvements for clinical trial design. I also collaborate with the Radiation Oncology department at the University of Michigan hospital. I am interested in designing efficient clinical trials that are motivated by oncology and rare diseases.
I have also been extensively involved in diversity, equity, and inclusion (DEI) both within the Biostatistics department and across the school.
For fun, I enjoy crafting ceramics (please take a mug! I have too many), flying through the air on a trapeze, and hanging out with my dog and cat.